Lisa O’Rourke

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

Stephen Johnston, John Pippen, Xavier Pivot et al. · Journal of Clinical Oncology · 2009 · 1K citations · Full text

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 231 citations

Hematological Malignancy, Surgical Oncology, Medicine +6

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch et al. · Haematologica · 2018 · 207 citations · Full text

Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer

Lee S. Schwartzberg, Sandra Franco, Allison Florance et al. · The Oncologist · 2010 · 189 citations · Full text